R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone
followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's
macroglobulinemia (Ballondor trial)